WEP Clinical’s Post

The WEP team have had a great first day at ESMO Congress 2024, in Barcelona. If you are at the event and would like to connect over the coming days to discuss how we can support your drug development and treatment access programs, please reach out to the team! Simon Clayton Ana Paula Tediosi Prashant Desai #ESMO24 #Oncology #DrugDevelopment #TreatmentAccess #WithEveryPatient

This #WorldDuchenneAwarenessDay, the WEP team is raising it’s voice in support of people living with Duchenne muscular dystrophy (DMD) around the world. We would like to acknowledge their individual journeys and successes and help raise awareness on the specific challenges and needs faced by individuals and families in this rare diseases community. We hope that through the portfolio of services we provide, WEP can continue to do its part to advance new treatment options and create equal access opportunities for all rare disease patients. #WithEveryPatient #RareDisease #DuchenneMuscularDystrophy

WEP is an industry leading provider of Expanded Access Programs. But did you know, we also support organizations with: - Open Label Extensions (OLE) - Rollover Studies   - Long-Term Observational Studies - Post Trial Access (PTA) Programs - Post-Approval Studies    Your company has options; lets talk about them!    Reach out to us at the email address below to speak to our team of experts. INFO@WEPCLINICAL.COM